Funding Acknowledgements Type of funding sources: None. Introduction Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown. Objective Evaluate the incidence of post-discharge thromboembolic and bleeding events and the role of thromboprophylaxis among COVID-19 patients. Methods We systematically searched PubMed, Embase and Cochrane databases, in March 2022, for interventional and observational studies. Results A total of 3 studies were included, providing a total 1569 patients, 325 in post-discharge anticoagulation and 1271 no discharge anticoagulation. In terms of outcomes assessed, both groups had similar symptomatic venous thrombotic events (pooled OR 0.43 [0.05, 3.79], P=0.14, I2=50%) and combined symptomatic and asymptomatic events pooled OR 0.63 [0.14, 2.79], P=0.54, I2=34%). Regarding bleeding events, no statistically significant difference was observed in all bleeding (major and non-major) events (pooled OR 2.85 [0.71, 11.43], P=0.14, I2=50%). Conclusion According to our meta-analysis, in patients hospitalized with COVID-19, extended thromboprophylaxis does not provide additional clinical benefit.